Resolutions of the Annual General Meeting of Biohit Oyj

The Annual General Meeting (AGM) of Biohit Oyj held on Wednesday 13 April 2011 approved the financial statements of the parent company and the consolidated financial statements, and discharged the members of the Board of Directors and the President and CEO from liability for the financial year 2010.

Distribution of dividends

In accordance with the proposal by the Board of Directors, the AGM decided that no dividends be paid for the financial year 2010, and that the parent company loss of EUR 534,475.32 be transferred to the retained profit and loss account.

Members of the Board of Directors

The AGM decided that the number of members of the Board of Directors would be seven (7). Furthermore, the AGM re-elected the following members to the Board until the end of the next AGM: MSc (Eng.) Kalle Kettunen, Professor Osmo Suovaniemi, Professor Mikko Salaspuro and MSc (Soc. Sc.) Eero Lehti. CEO Petteri Kilpinen, MSc (Eng.) Seppo Luode and CFO Saila Miettinen-Lähde were elected as new members.

Additionally, the AGM decided that the chairman of the Board of Directors would be paid a monthly fee of EUR 1,600 and the ordinary members would be paid a monthly fee of EUR 1,500.

Auditors

The AGM elected authorised public accountants Ernst & Young Oy as the company’s auditors, with APA Erkka Talvinko as the head auditor, until the end of the next AGM.

Authorisation of the Board of Directors to decide on the issue of shares and to issue special rights entitling the receipt of shares

The AGM decided to authorise the Board to decide on the issue of shares and to issue the special rights referred to in Chapter 10, section 1 of the Limited Liability Companies Act entitling the receipt of shares with the following terms and conditions:

The maximum number of new Series B shares to be issued pursuant to the special rights is 2,000,000, which corresponds to approximately 20% of the company’s Series B shares.

The authorisation includes the Board of Directors’ entitlement to decide on all terms and conditions regarding the issue of shares and the issue of special rights. The issue of shares and the issue of special rights entitling to the receipt of shares can occur deviant from the subscription right of the shareholders (special issue). The authorisation remains valid for three years from the resolution of the GM.
 

All decisions of the AGM were made unanimously. The minutes of the AGM will be available for review by shareholders by 15 April 2011 on the company’s website (www.biohit.com/investors) and at the corporate headquarters of Biohit, located at Laippatie 1, 00880 Helsinki.



Further information:

Jussi Heiniö, President and CEO
Tel: +358 (0) 9 773 861
jussi.heinio@biohit.com

Distribution:

NASDAQ OMX Helsinki Oy
Central storage facility (www.oam.fi)
Press
www.biohit.com


About Biohit Oyj:

Biohit Oyj is a globally operating Finnish biotechnology company that was established in 1988. The company’s mission is to improve human health and quality of life. The company follows a goal-directed and long-term innovation and patenting strategy.
Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective liquid handling solutions for laboratory work as well as diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract.

Biohit has two business segments: liquid handling and diagnostics. Liquid handling products include electronic and mechanical pipettes, disposable tips as well as pipette maintenance and calibration services for research institutions, healthcare and industrial laboratories.

The diagnostics business comprises products and analysis systems for the early diagnosis and prevention of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and H. pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of intestinal bleeding that indicates a risk of colorectal cancer. Acetium reduces the amount of carcinogenic acetaldehyde in an anacidic stomach.

The Biohit Group employs around 420 people. The company is headquartered in Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia, India, China, Japan and the USA. The company also has a representative office in Singapore. Biohit's products are also sold through about 200 distributors in 70 countries.

Since 1999, Biohit's Series B share has been quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group and is traded under the code BIOBV.

Read more at www.biohit.com